{"id":390852,"date":"2017-11-17T00:00:00","date_gmt":"2017-11-17T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0008-2017-biopharma-systemic-lupus-erythematosus-disease-landscape-and-forecast-g7-2017\/"},"modified":"2026-04-23T11:40:50","modified_gmt":"2026-04-23T11:40:50","slug":"dlsfim0008-2017-biopharma-systemic-lupus-erythematosus-disease-landscape-and-forecast-g7-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0008-2017-biopharma-systemic-lupus-erythematosus-disease-landscape-and-forecast-g7-2017\/","title":{"rendered":"Systemic Lupus Erythematosus | Disease Landscape and Forecast | G7 | 2017"},"content":{"rendered":"<p>Systemic lupus erythematosus (SLE) is a complex disease characterized by distinct manifestations. Currently, most treatments available to treat\u00a0SLE\u00a0are used off-label. The approval of Benlysta in 2011 marked the first new drug to be launched for\u00a0SLE\u00a0in more than 50 years. However,\u00a0SLE\u00a0remains an area of high unmet need, and significant opportunities exist for pharmaceutical companies that can successfully launch optimal treatment for the indication. Although\u00a0the heterogeneous nature of the disease impedes drug development and drug companies face formidable challenges ranging from trial design during development to getting reimbursement postapproval, multiple therapies are currently in early- and late-phase development for\u00a0SLE, and the list is only growing. In this complex environment, we expect the\u00a0SLE\u00a0market to increase by more than 200% during the 2016-2026 forecast period, largely driven by the entry and uptake of premium-priced biologics.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>How large is the drug-treated\u00a0SLE\u00a0population, and how is it going to emerge during the 2016-2026 forecast period?<\/li>\n<li>What proportion of\u00a0SLE\u00a0patients suffer from nonrenal and renal disease, respectively?<\/li>\n<li>What current treatments are available for\u00a0SLE, and which are the most important drugs and why? How is the market for these current treatments going to evolve during the 2016-2026 forecast period in both the renal and nonrenal populations?<\/li>\n<li>How is\u00a0SLE\u00a0market going to evolve over the next 10 years in the renal and nonrenal populations? Which emerging therapies are expected to get approved and drive growth for the market?<\/li>\n<li>What are the drivers and constraints in the\u00a0SLE\u00a0market?<\/li>\n<\/ul>\n<p><strong>Scope:<\/strong><\/p>\n<p><strong>Markets covered:\u00a0<\/strong>United States, France, Germany, Italy, Spain, United Kingdom, and Japan.<\/p>\n<p><strong>Primary research:<\/strong>\u00a018 country-specific interviews with rheumatologists and nephrologists.<\/p>\n<p><strong>Epidemiology:<\/strong>\u00a0Total diagnosed prevalence of\u00a0SLE, diagnosed prevalence of nonrenal\u00a0SLE, diagnosed prevalence of renal\u00a0SLE\u00a0(LN), total drug-treated\u00a0SLE\u00a0population, drug-treated nonrenal\u00a0SLE\u00a0population, drug-treated renal\u00a0SLE\u00a0(LN) population.<\/p>\n<p><strong>Population segments in market forecast:<\/strong>\u00a0Total population, nonrenal\u00a0SLE\u00a0population, renal\u00a0SLE\u00a0(LN) population.<\/p>\n<p><strong>Emerging therapies:\u00a0<\/strong>Phase II: 20 drugs; Phase III: 6 drugs; preregistration: 1 drug; registered: 1 drug. Coverage of 8 select preclinical and Phase I products.<\/p>\n","protected":false},"template":"","class_list":["post-390852","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-systemic-lupus-erythematosus","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390852","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390852\/revisions"}],"predecessor-version":[{"id":393976,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390852\/revisions\/393976"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390852"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}